Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JKN2306 Phase 1 SAD and Food Effect Study
NCT07412938Phase 1Completed
- Sponsor
- Joincare Pharmaceutical
- Start
- Feb 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JKN2306 in acute pain, sponsored by Joincare Pharmaceutical. Primary endpoint: Safety and tolerability at 15 days. Started Feb 2025; status: completed.
02
Drugs
JKN2306
03
Conditions
acute pain
Beyond the preview
Go deeper on NCT07412938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07412938.